Finnvectors

FinnVector is a world-leading Contract Development and Manufacturing Organization (CDMO) specializing in the production of viral vector-based gene therapies. Based in Kuopio, Finland, the company provides end-to-end services ranging from research-grade batches to commercial-scale GMP manufacturing. FinnVector is notably responsible for the production of Adstiladrin, the first gene therapy approved by the FDA for the treatment of high-risk, BCG-unresponsive non-muscle invasive bladder cancer. As a subsidiary of Ferring Pharmaceuticals, it leverages decades of expertise in adenoviral, adeno-associated viral (AAV), and lentiviral vector technologies. The company operates state-of-the-art facilities, including one of the world's first commercial-scale gene therapy manufacturing units, FinVector's Fin3 facility.